Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30388448.
- Also identified by DOI 10.1016/j.cell.2018.10.032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diseases leading to immune activation and autoinflammatory phenotypes may provide a reservoir of potentially druggable pathways for optimizing immune adjuvants or boosting antitumor immune responses. Now, Xia et al. report that lipophilic statins or biphosphonates, targeting the mevalonate pathway, act as efficient vaccine adjuvants and synergize with anti-PD1 against cancer.
Medical subject headings
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Vaccines